Where Global Innovation
and Capital Meet
Sectors Art of CVCConsumerEnergyFinancialHealthIndustrialITMediaServicesStartupsTelecomsTransportUniversity

Page 224

We Company releases billion-dollar IPO filing

SoftBank-backed workspace provider We Company has filed for an initial public offering in which it reportedly expects to raise up to $4bn.

Aug 14, 2019

Jazz carries away Cavion in $313m deal

Novartis and Eli Lilly are exiting the neurological disease therapy developer in an acquisition that will involve $52.5m upfront and up to $250m in milestone payments.

Aug 14, 2019

TopFunnel sucks in Clara Labs

Virtual scheduling assistant developer Clara has been acquired by recruitment services provider TopFunnel two years after raising $7m from investors including Slack Fund.

Aug 14, 2019

Caterwings swallows Lemoncat in acquisition deal

Rocket Internet-owned catering services provider Caterwings has paid an eight-figure sum for rival Lemoncat, which counted Rocket Internet as an investor.

Aug 14, 2019

Diageo downs Seedlip in acquisition

Diageo has acquired a majority share of non-alcoholic spirits provider Seedlip, building on an investment from its Distill Ventures accelerator in 2016.

Aug 14, 2019

Vector comes down to earth

Kanematsu-backed microsatellite launch company Vector has halted operations indefinitely after a major change in financing, less than a year after lining up $70m in series B capital.

Aug 13, 2019

Celect sells to Nike

Nike has paid an undisclosed amount for retail analytics software developer Celect, which had raised $30m from investors including NGP Partners.

Aug 13, 2019

Cisco to record Voicea acquisition

Cisco is set to buy portfolio company memo-transcription software provider Voicea in a deal that would allow Alphabet, Microsoft, Salesforce and Workday to exit.

Aug 12, 2019

Entuity arrives at Park Place

Park Place has purchased the network analytics software provider in a deal of undisclosed size that will enable Mitsubishi to exit.

Aug 12, 2019

Bayer buys BlueRock for $600m

Bayer will pay up to $600 for the 59.2% stake in engineered-cell therapy developer BlueRock Therapeutics it does now own, following a $225m round in 2016.

Aug 9, 2019
© 2025 Mawsonia Ltd. All rights reserved.
test reg

Login

Not yet subscribed?

See your subscription offers here